Skip to main content

Table 3 Drugs in clinical trials for PDAC targeting cancer associated stroma

From: Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis

Compound Combination Target Stage of patients Trial phase Ref Outcome
Vismodegib Gemcitabine Hedgehog signaling Stage IV PDAC Phase I/II [150] Non- significant [151]
PEGPH20 Gemcitabine, nab-paclitaxel, Hyaluronic acid Stage IV PDAC Phase II [124] Ongoing
EF-002 Dose escalation Activity of macrophages Solid tumor Phase I [152] Ongoing
Paricalcitol Gemcitabine, nab-paclitaxel metabolic pathway Advanced PC Phase I [153] Ongoing
MEDI4736 Gemcitabine, nab-paclitaxel C-X-C chemokine receptor type 2 Stage IV PDAC Phase I/II [154] Ongoing
Defactinib PD-1 FAK signaling Solid tumor Phase I/II [155] Ongoing
GSK2256098 Tremetinib FAK signaling PDAC Phase II [156] Ongoing
retinoic acid Gemcitabine, nab-paclitaxel Cancer associated fibroblasts PDAC Phase I [157] Ongoing
AM0010 FOLFOX, 5-FU, leucovorin Interleukins-10 Solid tumor Phase III [158] Ongoing
Pembrolizumab Paricalcitol, gemcitabine, nabpaclitaxel PD-1 Resectable PC Phase I [159] Ongoing
Cabiralizumab Nivolumab Colony-stimulating factor-1 receptor Solid tumor Phase I [160] Ongoing
Sonidegib Gemcitabine, nab-paclitaxel Hedgehog signaling Stage IV PDAC Phase I/II [161] Completed, Data not provided